Fisetin was also found to inhibit mTOR and PI3K/Akt signaling in NSCLC cells, both of which are important in both thoracic cancer biology and YB-1 regulation (see section “Translational Regulation of YB-1”) (Khan et al., 2012). This evidence concerns the gene AKT1 and non-small cell lung carcinoma.